Hyphens Pharma International Ltd.

Belkins
“Together We Can!” – With strong belief that Asians can contribute to healthcare of this world through passion, hard work and innovation, Hyphens Pharma International Limited, listed on Catalist, SGX-ST, is today Singapore's leading specialty pharmaceutical and consumer healthcare group. Leveraging on our diverse footprint in ASEAN countries, we have a direct presence in five ASEAN countries – Singapore (HQ), Indonesia, Malaysia, the Philippines and Vietnam, and supplemented by a marketing and distribution network covering six other markets – Bangladesh, Brunei, Cambodia, Hong Kong, Myanmar and Oman.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

news image

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

news image

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

PharmaNewsIntelligence | April 07, 2020

news image

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More

NO SINGLE MANUFACTURER CAN MEET CORONAVIRUS VACCINE GLOBAL DEMAND, SAYS MODERNA CEO

Cnbc | May 13, 2020

news image

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand. Regeneron CEO Leonard Schleifer, whose company is devel...

Read More
news image

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More
news image

BUSINESS INSIGHTS

CULLINAN ONCOLOGY FORMS STRATEGIC COLLABORATION AGREEMENT WITH MOUNT SINAI TO ADVANCE ORAL HPK1 PROTEIN DEGRADER FOR CANCER TREATMENT

Cullinan Oncology, Inc. | January 10, 2022

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced the Company has entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai to develop novel small molecule immune modulators.​ This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor...

Read More
news image

GSK, VIR USE CRISPR, ARTIFICIAL INTELLIGENCE TO FIND COVID-19 CURE

PharmaNewsIntelligence | April 07, 2020

GSK is partnering with Vir Biotechnology to use CRISPR and artificial intelligence to identify anti-viral compounds that can treat coronaviruses, including COVID-19. GlaxoSmithKline (GSK) and Vir Biotechnology recently announced a collaboration to enhance COVID-19 drug discovery through the use of CRISPR and artificial intelligence.For more coronavirus updates, visit our resource page, updated twice daily by Xtelligent Healthcare Media. The partnership will initially focus on accelerating the de...

Read More
news image

NO SINGLE MANUFACTURER CAN MEET CORONAVIRUS VACCINE GLOBAL DEMAND, SAYS MODERNA CEO

Cnbc | May 13, 2020

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand. Regeneron CEO Leonard Schleifer, whose company is devel...

Read More